Travere Therapeutics' Other Working Capital Changes rose 169.33% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 million, marking a year-over-year increase of 167.75%. This contributed to the annual value of -$6.1 million for FY2024, which is 61.24% up from last year.
Latest data reveals that Travere Therapeutics reported Other Working Capital Changes of -$6.1 million as of FY2024, which was up 61.24% from -$15.8 million recorded in FY2023.
Over the past 5 years, Travere Therapeutics' Other Working Capital Changes peaked at $38.3 million during FY2021, and registered a low of -$15.8 million during FY2023.
Over the past 3 years, Travere Therapeutics' median Other Working Capital Changes value was -$12.9 million (recorded in 2022), while the average stood at -$11.6 million.
As far as peak fluctuations go, Travere Therapeutics' Other Working Capital Changes skyrocketed by 2,174.04% in 2020, and later slumped by 133.76% in 2022.
Over the past 5 years, Travere Therapeutics' Other Working Capital Changes (Yearly) stood at $4.3 million in 2020, then surged by 787.81% to $38.3 million in 2021, then crashed by 133.76% to -$12.9 million in 2022, then fell by 22.04% to -$15.8 million in 2023, then skyrocketed by 61.24% to -$6.1 million in 2024.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value